Updated Management Guidelines for Adenosine Deaminase Deficiency
The Journal of Allergy and Clinical Immunology: In Practice · 2023
DOI: 10.1016/j.jaip.2023.01.032 ↗Kurz gefasst
Leitlinie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023. Verfasst von Eyal Grunebaum und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Allergy, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Immunology, Faculty of Medicine, Universi…. Hauptthemen laut MEDLINE: Agammaglobulinemia, Hematopoietic Stem Cell Transplantation, Severe Combined Immunodeficiency. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 97 Literaturangaben.
Abstract (Originalsprache)
Inherited defects in the adenosine deaminase (ADA) gene typically cause severe combined immunodeficiency. In addition to infections, ADA-deficient patients can present with neurodevelopmental, behavioral, hearing, skeletal, lung, heart, skin, kidney, urogenital, and liver abnormalities. Some patients also suffer from autoimmunity and malignancies. In recent years, there have been remarkable advances in the management of ADA deficiency. Most ADA-deficient patients can be identified by newborn screening for severe combined immunodeficiency, which facilitates early diagnosis and treatment of asymptomatic infants. Most patients benefit from enzyme replacement therapy (ERT). Allogeneic hematopoietic cell transplantation from an HLA-matched sibling donor or HLA-matched family member donor with no conditioning is currently the preferable treatment. When matched sibling donor or matched family member donor is not available, autologous ADA gene therapy with nonmyeloablative conditioning and ERT withdrawal, which is reported in recent studies to result in 100% overall survival and 90% to 95% engraftment, should be pursued. If gene therapy is not immediately available, ERT can be continued for a few years, although its excessive cost might be prohibitive. The recent improved outcome of hematopoietic cell transplantation using HLA-mismatched family-related donors or HLA-matched unrelated donors, after reduced-intensity conditioning, suggests that such procedures might also be considered rather than continuing ERT for prolonged periods. Long-term follow-up will further assist in determining the optimal treatment approach for ADA-deficient patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Immunology and Allergy, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: eyal.grun…
- Department of Paediatric Immunology and Gene Therapy, Great Ormond Street Hospital, London, United Kingdom.
- Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada.
- Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, and the Università Vita-Salute San Raffaele, Milan, Italy.
- Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, Calif.
Zitieren
APA
Grunebaum, E., Booth, C., Cuvelier, G. D. E., Loves, R., Aiuti, A., & Kohn, D. B. (2023). Updated Management Guidelines for Adenosine Deaminase Deficiency. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2023.01.032
Vancouver
Grunebaum E, Booth C, Cuvelier GDE, Loves R, Aiuti A, Kohn DB. Updated Management Guidelines for Adenosine Deaminase Deficiency. The Journal of Allergy and Clinical Immunology: In Practice. 2023. doi:10.1016/j.jaip.2023.01.032
BibTeX
@article{Grunebaum2023,
author = {Grunebaum, Eyal and Booth, Claire and Cuvelier, Geoffrey D E and Loves, Robyn and Aiuti, Alessandro and Kohn, Donald B},
title = {Updated Management Guidelines for Adenosine Deaminase Deficiency},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
doi = {10.1016/j.jaip.2023.01.032}
}
EUVIMED